A Phase 2 Prospective Trial of Dabrafenib With Stereotactic Radiosurgery in BRAFV600E Melanoma Brain Metastases
Phase of Trial: Phase II
Latest Information Update: 04 Nov 2016
At a glance
- Drugs Dabrafenib (Primary)
- Indications Brain metastases; Malignant melanoma
- Focus Biomarker; Therapeutic Use
- 28 Oct 2016 Status changed from active, no longer recruiting to completed.
- 18 Feb 2015 Planned End Date changed from 1 Oct 2015 to 1 Oct 2016 as reported by ClinicalTrials.gov record.
- 18 Feb 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.